ACHV Achieve Life Sciences Inc.

1.81
+0.04  (+2%)
Previous Close 1.77
Open 1.8
Price To Book 1.27
Market Cap 14,656,951
Shares 8,097,763
Volume 95,248
Short Ratio
Av. Daily Volume 208,064

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data met primary endpoint in 3/4 arms - June 11, 2019. Data to be presented at SRNT-E Conference, September 12-14, 2019.
Cytisine
Smoking cessation

Latest News

  1. /C O R R E C T I O N -- Achieve Life Sciences, Inc./
  2. Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
  3. Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
  4. Did You Manage To Avoid Achieve Life Sciences's (NASDAQ:ACHV) Painful 55% Share Price Drop?
  5. Achieve Life Sciences Says Mid-Stage Data For Smoking Cessation Drug Accepted For Presentation At Conference
  6. Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
  7. ACHV: ORCA-1 Topline Results and Comparison
  8. Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
  9. Achieve Receives $4.2 Million from Exercise of Warrants
  10. ACHV: 1Q:19 Financial & Operational Update
  11. Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
  12. Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
  13. Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
  14. ACHV: Final Enrollee, Final Visit